Review





Similar Products

oral squamous cell cancer tissue array with adjacent normal tongue tissue, including tnm and pathology grade, 60 cases/60 cores, replacing or601b  (AMS Biotechnology)
98
AMS Biotechnology oral squamous cell cancer tissue array with adjacent normal tongue tissue, including tnm and pathology grade, 60 cases/60 cores, replacing or601b
Oral Squamous Cell Cancer Tissue Array With Adjacent Normal Tongue Tissue, Including Tnm And Pathology Grade, 60 Cases/60 Cores, Replacing Or601b, supplied by AMS Biotechnology, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pathologe/Oral+squamous+cell+cancer+tissue+array+with+adjacent+normal+tongue+tissue%2C+including+TNM+and+pathology+grade%2C+60+cases%2F60+cores%2C+replacing+OR601b/custom%40or601c%4042872524
Average 98 stars, based on 1 article reviews
oral squamous cell cancer tissue array with adjacent normal tongue tissue, including tnm and pathology grade, 60 cases/60 cores, replacing or601b - by Bioz Stars, 2026-11
98/100 stars
  Buy from Supplier
phenoimager ht automated quantitative pathology imaging system  (Akoya Biosciences)
99
Akoya Biosciences phenoimager ht automated quantitative pathology imaging system
Phenoimager Ht Automated Quantitative Pathology Imaging System, supplied by Akoya Biosciences, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pathologe/PhenoImager+HT/pm42867637-78-11-18
Average 99 stars, based on 1 article reviews
phenoimager ht automated quantitative pathology imaging system - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier
pathological plasma p tau217  (Fujirebio Inc)
99
Fujirebio Inc pathological plasma p tau217
Predictive performance for Aβ-PET positivity Predictive performance of p-tau markers is shown in panel A, and Aβ, GFAP, and NFL in panel B. Biomarkers were examined as continuous variables. Unadjusted logistic regression; discrimination quantified by AUCs (95% CI). PiB-PET scan and visual read of Aβ positivity were available for 46 participants at <t>baseline.</t> <t>P-tau217</t> was measured with both Lumipulse assay and NULISAseq™ CNS Disease Panel 120, all other markers were measured with NULISAseq™ CNS Disease Panel 120. Aβ=beta-amyloid; AUC=area under the curve; GFAP=glial fibrillary acidic protein; NFL=neurofilament light chain; PiB-PET=Pittsburgh compound B positron emission tomography; p-tau=phosphorylated tau.
Pathological Plasma P Tau217, supplied by Fujirebio Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pathologe/Lumipulse+G+pTau+217+Plasma/med_rxiv__64898__2026__10__02__26364486-123-12-15
Average 99 stars, based on 1 article reviews
pathological plasma p tau217 - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier
digital pathological image analysis software  (Servicebio Inc)
86
Servicebio Inc digital pathological image analysis software
Predictive performance for Aβ-PET positivity Predictive performance of p-tau markers is shown in panel A, and Aβ, GFAP, and NFL in panel B. Biomarkers were examined as continuous variables. Unadjusted logistic regression; discrimination quantified by AUCs (95% CI). PiB-PET scan and visual read of Aβ positivity were available for 46 participants at <t>baseline.</t> <t>P-tau217</t> was measured with both Lumipulse assay and NULISAseq™ CNS Disease Panel 120, all other markers were measured with NULISAseq™ CNS Disease Panel 120. Aβ=beta-amyloid; AUC=area under the curve; GFAP=glial fibrillary acidic protein; NFL=neurofilament light chain; PiB-PET=Pittsburgh compound B positron emission tomography; p-tau=phosphorylated tau.
Digital Pathological Image Analysis Software, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pathologe/analysis+digital+image+pathology+software/pmc13251493-65-9-6
Average 86 stars, based on 1 article reviews
digital pathological image analysis software - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier
electromyography (emg) research  (MyoLearn)
99
MyoLearn electromyography (emg) research
Predictive performance for Aβ-PET positivity Predictive performance of p-tau markers is shown in panel A, and Aβ, GFAP, and NFL in panel B. Biomarkers were examined as continuous variables. Unadjusted logistic regression; discrimination quantified by AUCs (95% CI). PiB-PET scan and visual read of Aβ positivity were available for 46 participants at <t>baseline.</t> <t>P-tau217</t> was measured with both Lumipulse assay and NULISAseq™ CNS Disease Panel 120, all other markers were measured with NULISAseq™ CNS Disease Panel 120. Aβ=beta-amyloid; AUC=area under the curve; GFAP=glial fibrillary acidic protein; NFL=neurofilament light chain; PiB-PET=Pittsburgh compound B positron emission tomography; p-tau=phosphorylated tau.
Electromyography (Emg) Research, supplied by MyoLearn, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pathologe/Electromyography+(EMG)+Research/custom%40emg%4042506876
Average 99 stars, based on 1 article reviews
electromyography (emg) research - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier
pathology fluorescent slide scanning system  (Olympus)
99
Olympus pathology fluorescent slide scanning system
Predictive performance for Aβ-PET positivity Predictive performance of p-tau markers is shown in panel A, and Aβ, GFAP, and NFL in panel B. Biomarkers were examined as continuous variables. Unadjusted logistic regression; discrimination quantified by AUCs (95% CI). PiB-PET scan and visual read of Aβ positivity were available for 46 participants at <t>baseline.</t> <t>P-tau217</t> was measured with both Lumipulse assay and NULISAseq™ CNS Disease Panel 120, all other markers were measured with NULISAseq™ CNS Disease Panel 120. Aβ=beta-amyloid; AUC=area under the curve; GFAP=glial fibrillary acidic protein; NFL=neurofilament light chain; PiB-PET=Pittsburgh compound B positron emission tomography; p-tau=phosphorylated tau.
Pathology Fluorescent Slide Scanning System, supplied by Olympus, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pathologe/VS120+Virtual+Slide+Microscope+Virtual+Slide+Microscopy/pm41764845-95-6-11
Average 99 stars, based on 1 article reviews
pathology fluorescent slide scanning system - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier
pathology slide scanner  (Olympus)
99
Olympus pathology slide scanner
Predictive performance for Aβ-PET positivity Predictive performance of p-tau markers is shown in panel A, and Aβ, GFAP, and NFL in panel B. Biomarkers were examined as continuous variables. Unadjusted logistic regression; discrimination quantified by AUCs (95% CI). PiB-PET scan and visual read of Aβ positivity were available for 46 participants at <t>baseline.</t> <t>P-tau217</t> was measured with both Lumipulse assay and NULISAseq™ CNS Disease Panel 120, all other markers were measured with NULISAseq™ CNS Disease Panel 120. Aβ=beta-amyloid; AUC=area under the curve; GFAP=glial fibrillary acidic protein; NFL=neurofilament light chain; PiB-PET=Pittsburgh compound B positron emission tomography; p-tau=phosphorylated tau.
Pathology Slide Scanner, supplied by Olympus, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pathologe/VS200+Research+Slide+Scanner/10__26599_slash_fshw__2026__9251162-65-6-11
Average 99 stars, based on 1 article reviews
pathology slide scanner - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier
polaris automated quantitative pathology imaging system  (Vectra Laboratories)
86
Vectra Laboratories polaris automated quantitative pathology imaging system
Predictive performance for Aβ-PET positivity Predictive performance of p-tau markers is shown in panel A, and Aβ, GFAP, and NFL in panel B. Biomarkers were examined as continuous variables. Unadjusted logistic regression; discrimination quantified by AUCs (95% CI). PiB-PET scan and visual read of Aβ positivity were available for 46 participants at <t>baseline.</t> <t>P-tau217</t> was measured with both Lumipulse assay and NULISAseq™ CNS Disease Panel 120, all other markers were measured with NULISAseq™ CNS Disease Panel 120. Aβ=beta-amyloid; AUC=area under the curve; GFAP=glial fibrillary acidic protein; NFL=neurofilament light chain; PiB-PET=Pittsburgh compound B positron emission tomography; p-tau=phosphorylated tau.
Polaris Automated Quantitative Pathology Imaging System, supplied by Vectra Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pathologe/automated+imaging+pathology+polaris+quantitative+system/pm42319929-330-9-8
Average 86 stars, based on 1 article reviews
polaris automated quantitative pathology imaging system - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier
halo digital pathology platform  (Indica Labs)
86
Indica Labs halo digital pathology platform
Predictive performance for Aβ-PET positivity Predictive performance of p-tau markers is shown in panel A, and Aβ, GFAP, and NFL in panel B. Biomarkers were examined as continuous variables. Unadjusted logistic regression; discrimination quantified by AUCs (95% CI). PiB-PET scan and visual read of Aβ positivity were available for 46 participants at <t>baseline.</t> <t>P-tau217</t> was measured with both Lumipulse assay and NULISAseq™ CNS Disease Panel 120, all other markers were measured with NULISAseq™ CNS Disease Panel 120. Aβ=beta-amyloid; AUC=area under the curve; GFAP=glial fibrillary acidic protein; NFL=neurofilament light chain; PiB-PET=Pittsburgh compound B positron emission tomography; p-tau=phosphorylated tau.
Halo Digital Pathology Platform, supplied by Indica Labs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pathologe/digital+halo+pathology+platform/pm42320171-180-14-19
Average 86 stars, based on 1 article reviews
halo digital pathology platform - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier
mpias 500 multimedia color pathology graphic analysis system  (Technology Development Co)
86
Technology Development Co mpias 500 multimedia color pathology graphic analysis system
Predictive performance for Aβ-PET positivity Predictive performance of p-tau markers is shown in panel A, and Aβ, GFAP, and NFL in panel B. Biomarkers were examined as continuous variables. Unadjusted logistic regression; discrimination quantified by AUCs (95% CI). PiB-PET scan and visual read of Aβ positivity were available for 46 participants at <t>baseline.</t> <t>P-tau217</t> was measured with both Lumipulse assay and NULISAseq™ CNS Disease Panel 120, all other markers were measured with NULISAseq™ CNS Disease Panel 120. Aβ=beta-amyloid; AUC=area under the curve; GFAP=glial fibrillary acidic protein; NFL=neurofilament light chain; PiB-PET=Pittsburgh compound B positron emission tomography; p-tau=phosphorylated tau.
Mpias 500 Multimedia Color Pathology Graphic Analysis System, supplied by Technology Development Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pathologe/analysis+gait+system/pm42309496-267-0-13
Average 86 stars, based on 1 article reviews
mpias 500 multimedia color pathology graphic analysis system - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

Image Search Results


Predictive performance for Aβ-PET positivity Predictive performance of p-tau markers is shown in panel A, and Aβ, GFAP, and NFL in panel B. Biomarkers were examined as continuous variables. Unadjusted logistic regression; discrimination quantified by AUCs (95% CI). PiB-PET scan and visual read of Aβ positivity were available for 46 participants at baseline. P-tau217 was measured with both Lumipulse assay and NULISAseq™ CNS Disease Panel 120, all other markers were measured with NULISAseq™ CNS Disease Panel 120. Aβ=beta-amyloid; AUC=area under the curve; GFAP=glial fibrillary acidic protein; NFL=neurofilament light chain; PiB-PET=Pittsburgh compound B positron emission tomography; p-tau=phosphorylated tau.

Journal: medRxiv

Article Title: Blood Biomarkers of Alzheimer’s Disease Neuropathology, Cognition, and Response to a Multidomain Lifestyle Intervention: Secondary analysis of the FINGER Randomized Controlled Dementia Risk Reduction Trial

doi: 10.64898/2026.10.02.26364486

Figure Lengend Snippet: Predictive performance for Aβ-PET positivity Predictive performance of p-tau markers is shown in panel A, and Aβ, GFAP, and NFL in panel B. Biomarkers were examined as continuous variables. Unadjusted logistic regression; discrimination quantified by AUCs (95% CI). PiB-PET scan and visual read of Aβ positivity were available for 46 participants at baseline. P-tau217 was measured with both Lumipulse assay and NULISAseq™ CNS Disease Panel 120, all other markers were measured with NULISAseq™ CNS Disease Panel 120. Aβ=beta-amyloid; AUC=area under the curve; GFAP=glial fibrillary acidic protein; NFL=neurofilament light chain; PiB-PET=Pittsburgh compound B positron emission tomography; p-tau=phosphorylated tau.

Article Snippet: The n (%) of Aβ-PET positives among those with normal, intermediate, and pathological plasma p-tau217 (Lumipulse) was 11/36 (31%), 4/6 (67%), and 4/4 (100%), respectively.

Techniques: Positron Emission Tomography

Associations between baseline biomarker levels and cognition (NTB Global cognition, primary trial outcome) Estimates (95% CI) were obtained from linear regression models (for baseline cognition, A) and mixed-effects models (for cognitive change, B), using marginal prediction methods to derive interpretable effect estimates. Results are interpreted as differences in baseline cognitive performance (A) or cognitive change in two years (B), per 1 standard deviation (SD) higher baseline biomarker level, in the whole cohort (irrespective of randomization). Negative estimates indicate worse cognitive performance or less favorable cognitive trajectory (less improvement) with increasing baseline biomarker levels. Analyses were adjusted for baseline age, sex, education, study site, APOE genotype, body mass index (BMI), and estimated glomerular filtration rate (eGFR) as an indicator of renal function. Baseline analysis n=1220 (Lumipulse p-tau217) and n=1223 (other biomarkers); longitudinal analysis n=1154 (Lumipulse p-tau217) and n=1157 (other biomarkers). Aβ=beta-amyloid; GFAP=glial fibrillary acidic protein; NFL=neurofilament light chain; NTB=neuropsychological test battery; p-tau=phosphorylated tau.

Journal: medRxiv

Article Title: Blood Biomarkers of Alzheimer’s Disease Neuropathology, Cognition, and Response to a Multidomain Lifestyle Intervention: Secondary analysis of the FINGER Randomized Controlled Dementia Risk Reduction Trial

doi: 10.64898/2026.10.02.26364486

Figure Lengend Snippet: Associations between baseline biomarker levels and cognition (NTB Global cognition, primary trial outcome) Estimates (95% CI) were obtained from linear regression models (for baseline cognition, A) and mixed-effects models (for cognitive change, B), using marginal prediction methods to derive interpretable effect estimates. Results are interpreted as differences in baseline cognitive performance (A) or cognitive change in two years (B), per 1 standard deviation (SD) higher baseline biomarker level, in the whole cohort (irrespective of randomization). Negative estimates indicate worse cognitive performance or less favorable cognitive trajectory (less improvement) with increasing baseline biomarker levels. Analyses were adjusted for baseline age, sex, education, study site, APOE genotype, body mass index (BMI), and estimated glomerular filtration rate (eGFR) as an indicator of renal function. Baseline analysis n=1220 (Lumipulse p-tau217) and n=1223 (other biomarkers); longitudinal analysis n=1154 (Lumipulse p-tau217) and n=1157 (other biomarkers). Aβ=beta-amyloid; GFAP=glial fibrillary acidic protein; NFL=neurofilament light chain; NTB=neuropsychological test battery; p-tau=phosphorylated tau.

Article Snippet: The n (%) of Aβ-PET positives among those with normal, intermediate, and pathological plasma p-tau217 (Lumipulse) was 11/36 (31%), 4/6 (67%), and 4/4 (100%), respectively.

Techniques: Biomarker Discovery, Standard Deviation, Filtration, Analysis, Battery

Intervention effect modification by baseline biomarker levels (outcome NTB Global cognition, primary trial outcome) Estimates (95% CI) were obtained from linear mixed-effects models, using marginal prediction methods to derive interpretable effect estimates. Estimates are interpreted as difference between the intervention and control groups in cognitive change per year; positive estimates indicate more favorable cognitive change in the intervention group. Biomarker × group × time interactions were examined to assess whether baseline biomarker levels modified the intervention effects on cognition, i.e., whether the differences in cognitive change between intervention and control groups differed by baseline biomarker levels. Interactions with p>0.05 indicate that the intervention effect did not significantly differ by baseline biomarker levels. Interactions were derived from models where biomarkers were entered as continuous variables, but for visualization, estimates for intervention effect are presented within biomarker strata (below median = blue diamond, above median = red circle). Analyses were adjusted for age, sex, education, study site, APOE genotype, body mass index (BMI), and estimated glomerular filtration rate (eGFR). Aβ=beta-amyloid; GFAP=glial fibrillary acidic protein; NFL=neurofilament light chain; NTB=neuropsychological test battery; p-tau=phosphorylated tau.

Journal: medRxiv

Article Title: Blood Biomarkers of Alzheimer’s Disease Neuropathology, Cognition, and Response to a Multidomain Lifestyle Intervention: Secondary analysis of the FINGER Randomized Controlled Dementia Risk Reduction Trial

doi: 10.64898/2026.10.02.26364486

Figure Lengend Snippet: Intervention effect modification by baseline biomarker levels (outcome NTB Global cognition, primary trial outcome) Estimates (95% CI) were obtained from linear mixed-effects models, using marginal prediction methods to derive interpretable effect estimates. Estimates are interpreted as difference between the intervention and control groups in cognitive change per year; positive estimates indicate more favorable cognitive change in the intervention group. Biomarker × group × time interactions were examined to assess whether baseline biomarker levels modified the intervention effects on cognition, i.e., whether the differences in cognitive change between intervention and control groups differed by baseline biomarker levels. Interactions with p>0.05 indicate that the intervention effect did not significantly differ by baseline biomarker levels. Interactions were derived from models where biomarkers were entered as continuous variables, but for visualization, estimates for intervention effect are presented within biomarker strata (below median = blue diamond, above median = red circle). Analyses were adjusted for age, sex, education, study site, APOE genotype, body mass index (BMI), and estimated glomerular filtration rate (eGFR). Aβ=beta-amyloid; GFAP=glial fibrillary acidic protein; NFL=neurofilament light chain; NTB=neuropsychological test battery; p-tau=phosphorylated tau.

Article Snippet: The n (%) of Aβ-PET positives among those with normal, intermediate, and pathological plasma p-tau217 (Lumipulse) was 11/36 (31%), 4/6 (67%), and 4/4 (100%), respectively.

Techniques: Modification, Biomarker Discovery, Control, Derivative Assay, Filtration, Battery